As there is concern regarding the high carcinogenic potential of melphalan (Mel), 725 patients with haematological malignancies who received allogeneic (n = 714) or syngeneic (n = 11) transplants over the last 26 years were followed-up to evaluate if melphalan was more likely to result in secondary malignant neoplasms (SMNs) than cyclophosphamide (Cy). Three hundred and ninety-five were treated with Cy/TBI and 330 with Mel/TBI. Twelve patients developed non-haematological SMN. Median time to develop a SMN was 7 years (range 2-17 years). Age-adjusted rate was significantly higher than in the general population (observed 12 expected 1.2, risk 10; P Ͻ 0.0001). The cumulative overall risk of developing a SMN at 2, 5, 10 and 15 years post transplant was 0.4% (95% CI 0.1-2.6%), 1.7% (95% CI 0.6-4.4%), 6.4% (95% CI 2.8-10.8%) and 6.6% (95% CI 3.4-12.4%), respectively. Even though age-adjusted rates were higher than the general population melphalan/TBI was not associated with higher age-adjusted risk than Cy/TBI (increased risk 7.9 vs 11.4; P = NS). The cumulative overall risk of SMNs was not different with CY/TBI or Mel/TBI (8/393 vs 4/363; 10 year risk 4.4%, 95% CI 1.8-10.6 vs 8.4%, 95% CI 2.9-22.9; P = NS). The risk was significantly higher with use of additional cranial or cranio-spinal irradiation (17.5% vs 2.7% at 10 years; P = 0.0241). Transplants for acute lymphatic leukaemia resulted in a higher incidence of SMNs than did transplants for other diseases (ALL: 17.4%, 95% CI 6.3-42.6%; other diseases: 3.4% (95% 1.3-8.5%, P = 0.0469). The risk of SMN for patients with chronic GVHD was 8.4% (95% CI 3.7-18.7%) as compared to 3.5% (95% CI 1-11.1%) for patients without chronic GVHD (P = NS). No factor was associated with independently increased risk in multivariate analysis. Use of melphalan and TBI for transplant conditioning does not appear to be associated with higher risk of second malignant neoplasms than cyclophosphamide Bone marrow transplantation has been increasingly used for the treatment of haematological and immunological disorders. Transplant conditioning regimens use alkylating agents as well as total body irradiation. Both of these modalities can be carcinogenic and there are growing concerns about transplant-induced malignancies. As the success rates of BMT have improved over the years, the population of long-term survivors who may be at increased risk of second malignancies has grown. A number of studies has estimated the risk of second malignancies post transplant [1] [2] [3] [4] and there are reports suggesting an increased risk of both haematological and non-haematological malignancies in patients receiving allogeneic and autologous transplants. 
Bone marrow transplantation has been increasingly used for the treatment of haematological and immunological disorders. Transplant conditioning regimens use alkylating agents as well as total body irradiation. Both of these modalities can be carcinogenic and there are growing concerns about transplant-induced malignancies. As the success rates of BMT have improved over the years, the population of long-term survivors who may be at increased risk of second malignancies has grown. A number of studies has estimated the risk of second malignancies post transplant [1] [2] [3] [4] and there are reports suggesting an increased risk of both haematological and non-haematological malignancies in patients receiving allogeneic and autologous transplants. 5 A multi-centre study involving almost 20 000 patients has recently been published analysing the risk of solid cancers after BMT. 6 Melphalan is becoming increasingly popular for conditioning prior to BMT because it causes no bladder toxicity and may have a superior anti-leukaemia effect. 7 However, there is concern regarding the high carcinogenic potential of melphalan in the non-transplant setting. [8] [9] [10] This single centre analysis was undertaken to evaluate the risk of second malignant neoplasms following allogeneic bone marrow transplantation after a variety of conditioning regimens. Secondary leukaemia and myelodysplastic syndromes are excluded in this analysis.
Materials and methods
Seven hundred and twenty-five patients who received allogeneic (n = 714) or syngeneic transplants (n = 11) were identified from the prospectively maintained leukaemia database at the Royal Marsden Hospital. 11 Transplants were carried out over the period . Patients transplanted for aplastic anaemia or Fanconi's anaemia were excluded from the analysis because of their predisposition to cancer. Patient characteristics are shown in Table 1 . Transplants were for AML (n = 378), ALL (n = 164), CML (n = 86), and other diseases (n = 97). Median patient age at the time of transplant was 26 years (range 9 months-58 years). Donors were HLA-identical siblings (n = 636), mismatched family members (n = 40), matched unrelated (n = 38) or syngeneic twins (n = 11). All the patients were followed until 1 August 1998 or death. Syngeneic recipients did not receive GVHD prophylaxis. Cyclosporine alone was used as prophylaxis in 416 patients, cyclosporine and short-course methotrexate in 265, methotrexate alone in 15, and 19 received T cell depleted grafts. There were more patients who received cyclosporine alone as GVHD prophylaxis in the Cy/TBI arm (P = 0.001) while in Mel/TBI arm use of 10.5 Gy as the TBI dose was higher (P = 0.001). Details of the conditioning regimens have been previously published. [12] [13] [14] [15] In the cyclophosphamide group, the dose of TBI was 9.5Gy as a single fraction (n = 131), or 10.5 Gy as a single fraction (n = 98) and in 166 either higher dose or fractionated TBI was used. In the melphalan group, 9.5 Gy single fraction TBI was used in 95, 10.5 Gy single fraction in 227 and eight received a higher dose or fractionated TBI.
In addition to TBI, 128 patients also received cranial (n = 113) or craniospinal (n = 15) irradiation for CNS prophylaxis.
Cases of second malignant neoplasms (SMN) were identified from the case files, patient interviews and information from referring physicians. Data concerning histological findings, staging and treatment of SMN were obtained.
Statistical analysis
The follow-up period was 11 days to 15.3 years for patients receiving melphalan and 11 days to 26 years for those receiving cyclophosphamide. One hundred and thirty-four in the melphalan group and 185 in the cyclophosphamide group were followed for more than 1 year.
For individual patients, the number of person-years at risk was calculated from the date of transplant until last date of follow-up or death. To calculate the expected number of cancers in the study population, incidence rates were obtained from England and Wales cancer registers. 16 The ratio of observed to expected number of cancers and 95% confidence intervals were calculated assuming a Poisson distribution for the observed cancers. The cumulative overall risk of developing a SMN was calculated using the Kaplan-Meier method. 17 Impact of age at the time of graft (Ͻ15 years or Ͼ15 years), sex, diagnosis (AML, ALL, CML or others), GVHD prophylaxis (cyclosporine vs cyclosporine and methotrexate), conditioning regimen (Cyclo/TBI vs Mel/TBI), dose of TBI (9.5 Gy single fraction or 10.5 Gy single fraction), acute GVHD (present or absent), chronic GVHD (present or absent) were calculated using Kaplan-Meier method and compared using log rank test. Multivariate analysis using the Cox regression model was performed.
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Results
Twelve patients developed non-haematological SMN following allograft or syngeneic transplant. Table 2 shows the details of SMN. Sites of second malignancy were skin (basal cell: n = 2), oral cavity (squamous cell: n = 2), brain (PNET: n = 3), breast (adenocarcinoma: n = 2), colon (adenocarcinoma: n = 1) and thyroid (medullary cell: n = 1). One patient developed large cell non-Hodgkin's lymphoma with no evidence of EB virus. The median time elapsing between transplant and developing a SMN was 7 years (range 2-17 years).
The age-adjusted rate of SMNs was significantly higher than in the general population (observed 12, expected 1.2; increased risk of 10, P Ͻ 0.0001). The risk was significantly elevated for skin, brain, breast and thyroid cancer ( Table 3 ). The overall risk of developing a SMN at 2, 5, 10 and 15 years post transplant was 0.4% (95% CI 0.1-2.6%), 1.7% (95% CI 0.6-4.4%), 6.4% (95% CI 2.8-10.8%) and 6.6% (95% CI 3.4-12.4%), respectively ( Figure 1 ).
Comparison of melphalan and cyclophosphamide
There appeared to be no difference in the cumulative risk of SMN with use of cyclophosphamide or melphalan with TBI for conditioning (8/395 vs 4/330; P = NS) ( Figure 2 ). Also, TBI dose appeared to have no influence on the incidence of SMNs (9.5 vs 10.5 Gy, 4.5% vs 8.7%, P = NS). Both melphalan and cyclophosphamide were associated with a higher age-adjusted rate as compared to the general population (melphalan: O/E-4/0.53, risk: 7.6, P Ͻ 0.0001; cyclophosphamide: O/E-8/0.67, risk: 11.94; P Ͻ 0.0001) but there was no difference in the expected number of SMNs with cyclophosphamide or melphalan. It was not possible to evaluate the risk in the two groups for different anatomical sites due to the small number of patients. Age of the patient above or below 15 years was not associated with higher risk (7/532 vs 5/193; P = NS) and there was no influence of the sex of the patient on risk.
Transplants for acute lymphatic leukaemia appeared to have a higher incidence of SMN than did transplants for other diseases (ALL: 17.4%, 95%CI 6.3-42.6%; other dis- eases: 3.4%, 95% CI 1.3-8.5% P = 0.047, Figure 3 ). The risk of SMN was significantly higher in patients who received cranial or cranio-spinal irradiation (17.5% vs 2.7% at 10 years; P = 0.0241, Figure 4 ).
Acute and chronic GVHD
There was little influence of GVHD prophylaxis on incidence of SMNs (CyA: 7/416, CyA + MTX: 3/265). Five hundred and forty-six patients developed acute GVHD after transplant and seven developed second cancers, as compared to five out of 161 who did not develop acute GVHD (P = NS). Patients who developed chronic GVHD did not show a higher incidence of SMNs (7/228 vs 5/497; P = 0.22, Figure 5 ). The 10 year risk of developing a second cancer was 8.4% (95% CI 3.7-18.7) in patients with chronic GVHD as compared to 3.5% (95% CI 1-11.1) in patients not developing chronic GVHD.
Risk of second malignancy was not influenced by the type of immunosuppressive drugs used for the treatment of acute or chronic GVHD. In the multivariate analysis no predictor was associated with significantly higher risk of second malignant neoplasms.
Treatment and outcome of SMNs
All patients except one received treatment for the SMN. Details of treatment and outcome are shown in Table 4 . The patient with abdominal NHL died before commencing the therapy for the disease. Basal cell carcinoma was treated with local surgery in both patients and they are alive without recurrence. The two patients with breast cancer received modified mastectomies, local radiotherapy and adjuvant chemotherapy. One died with disseminated disease and one is alive with no evidence of cancer. Patients with oral malignancies were treated with surgery and local radiotherapy. Both died with advanced disease. The patient with medullary carcinoma of the thyroid was treated with radioiodine and is alive. One patient with PNET of the medulla is alive after surgery and radiotherapy with the disease under control, but the two with supratentorial PNETs died with disease. The case with carcinoma of the colon died after the surgery. Five patients out of 12 are alive (with no evidence of disease). The SMN was the main cause of death in all the patients who died.
Discussion
Use of high-dose chemo-radiotherapy for transplant conditioning is associated with various long-term complications including cataracts, sterility, pulmonary dysfunction and endocrine dysfunction 19, 20 and second malignancy. Most of these complications are treatable, but transplantinduced SMNs may not be as amenable as are other complications. Curtis et al 6 found that in a large population of transplanted patients, the risk for solid cancers was 2.7 times higher than in the general population. Risk increased with time, and at 15 years it was as high as 6.7%. In our study we observed a cumulative risk of 6.4% at 10 years and 8.7% at 15 years. The age-adjusted incidence of SMNs was 10 times higher than in the general population. The number of patients at risk beyond 10 years was relatively small and obviously this limits the ability to estimate the actual risk in long-term survivors. Although direct comparison with the IBMTR data may not be valid, it is interesting to note that overall incidence of SMN was higher in our cohort. This may partly be due to inclusion of basal cell skin cancers or comparatively small numbers in the present study but probably more due to under-reporting of cases from the many centres involved in the IBMTR study. The SMNs in our series included basal cell carcinoma, oral squamous cancers, adenocarcinoma breast, PNET, NHL and adenocarcinoma of colon. These are a few of the common cancers reported in other series as well. Transplantation may be associated with certain malignancies that do not have an established association with radiation. We had one case of medullary carcinoma of the thyroid that has no proven association with radiation, and Curtis et al 6 noticed a higher incidence of melanoma in patients who had received radiation, although this association has not been established.
The carcinogenic effect of radiation is time and age dependent, with long latent periods and a higher incidence in the younger population.
21-23 Surprisingly, we found no correlation with age and risk of SMN, possibly due to the relatively small number of patients younger than 15 years of age at the time of transplant. Even though the ageadjusted incidence was 7 and 11 times higher with melphalan and cyclophosphamide, respectively, there was no difference in incidence between cyclophosphamide/TBI and melphalan/TBI. All anticancer alkylating agents are recognised as being carcinogenic, and this varies among the drugs in this group. Melphalan is likely to have more carcinogenic potential than does cyclophosphamide and this is especially true for haematological malignancies. 8, 9 In one trial of chemotherapy for breast cancer, melphalan was associated with an 11.2% risk as compared to cyclophosphamide, which was associated with a 5.4% risk of developing a SMN. 10 In the MRC studies (I and II) for treatment of myeloma with single-agent melphalan or cyclophosphamide, melphalan-treated patients had a higher incidence of SMN. 8, 9 In accordance with these observations, it may be assumed that melphalan and TBI conditioning will be more carcinogenic and lead to a significantly increased risk of SMN. This was not observed in our series. With only 12 patients developing second malignancies the statistical power to identify differences is obviously low but to detect a difference of 2-4% between two regimens with a power of 95% almost 6000 patients will have to be followed up for 10 or more years which may be practically difficult. Although cyclophosphamide/TBI was in use prior to melphalan/TBI in our unit, it is important to note that in the melphalan/TBI group more patients received higher doses of TBI as compared to the cyclophosphamide/TBI group.
Those who received 9.5 Gy had an incidence similar to those who received 10.5 Gy. As most of our patients received single fraction TBI this finding was surprising because the experiences from Hiroshima and Chernobyl
Bone Marrow Transplantation established that risk is directly related to radiation dose. 21, 22 It is very likely that in transplant patients the deciding factor may not only be the conditioning therapy, but other factors including immunosuppression and immune dysfunction may play equally important roles. Use of cranial or cranio-spinal irradiation for CNS prophylaxis was associated with higher incidence of SMN but this lost its significance in multivariate analysis. The small number of patients with SMN in this study did not allow evaluation of the effect of cranial prophylaxis in melphalan/TBI and cyclophosphamide/TBI groups separately.
In a previous study, acute GVHD was associated with an increased risk of haematological SMN. 24 Chronic GVHD is a known risk factor for developing squamous cancers but its impact on other cancers seems equivocal. In our patients, there was no increased risk with either acute or chronic GVHD but this may be due to the small number of patients in this series. It is possible that deaths in the immediate post-transplant period reduced the number of patients at risk available for evaluation of impact of acute GVHD upon risk. It is also possible that the long-term immune dysfunction associated with chronic GVHD and its treatment are more carcinogenic. Curtis et al 6 found no effect of immune dysfunction on incidence of SMN but there was an increased incidence of melanoma and squamous cell carcinoma. All our patients with squamous carcinoma had chronic GVHD, and there was no difference relating to type of GVHD prophylaxis. T cell depletion is known to increase the risk of SMN specifically lymphoproliferative disorders, but as only 19 patients received T cell-depleted marrow in our study it was not possible to evaluate risk in this group.
It was observed that acute lymphatic leukaemia was associated with a higher risk for SMN than were other diseases although this lost its significance in multivariate analysis. The higher risk observed in univariate analysis may partly be explained by use of cranial radiation for CNS prophylaxis in most patients with ALL. Primary disease is known to influence the risk of SMN that may be partly due to the younger age of ALL patients at transplant, but our analysis failed to corroborate this finding.
Treatment of SMNs has met with limited success. Control was possible only in those cancers that are recognised as being relatively curable (in our series, basal cell carcinoma, medulloblastoma and breast cancer). Surgery is one of the important treatment modalities for most solid cancers, and patients with chronic GVHD face the problem of impaired healing of surgical wounds, making treatment even more difficult.
This study has excluded patients with haematological malignancies post transplant since it has been well established that the incidence of MDS and AML is increased in patients undergoing both allogeneic and autologous transplantation. We have observed a similar trend, with a 2% risk of developing MDS in patients treated for myeloma. 25 The combined risk of haematological malignancies and SMNs post allogeneic transplantation is thus likely to be high.
In conclusion, allogeneic bone marrow transplant has curative potential and has saved many lives in the last 25 years. Its use is increasing, and even though it is associated with some serious long-term sequelae, the potential advantages far outweigh these risks. Presently, there seems to be no alternative to radiation and high-dose alkylating agents for transplant conditioning. Although we did not find an influence of GVHD on the risk of SMNs it is possible that immune dysfunction may contribute and selective immunosuppression with more effective treatment of chronic GVHD may help reduce the risk. Melphalan is likely to have better anti-leukaemic activity, lower incidence of early transplant-related complications and is increasingly used for transplant conditioning therapy. Hence, it was reassuring to know that it does not appear to be associated with an increased incidence of second malignant neoplasms. Although choice of conditioning regimen does not seem to play a role in development of SMNs long-term follow-up is required. Diligent monitoring involving long-term follow-up should thus be undertaken in all long-term transplant survivors so that SMNs are detected as early as possible.
